Literature DB >> 29274564

The validity and reliability of screening measures for depression and anxiety disorders in multiple sclerosis.

Ruth Ann Marrie1, Lixia Zhang2, Lisa M Lix2, Lesley A Graff3, John R Walker3, John D Fisk4, Scott B Patten5, Carol A Hitchon6, James M Bolton7, Jitender Sareen7, Renée El-Gabalawy8, James J Marriott6, Charles N Bernstein6.   

Abstract

OBJECTIVE: We aimed to evaluate the validity and reliability of multiple screening measures for depression and anxiety for use in the clinical care of people with multiple sclerosis (MS).
METHODS: Participants with MS completed the Patient Health Questionnaire (PHQ-9), Hospital Anxiety and Depression Scale (HADS), Kessler-6 Distress Scale, PROMIS Emotional Distress Depression Short-Form 8a (PROMIS Depression) and Anxiety Short-Form 8a (PROMIS Anxiety), Generalized Anxiety Disorder 7-item Scale (GAD-7), and the Overall Anxiety and Severity Impairment Scale (OASIS). A subgroup repeated the screening measures two weeks later. All participants also completed a Structured Clinical Interview for DSM-IV-TR Axis I Disorders (SCID). For the screening measures we computed sensitivity, specificity, positive predictive and negative predictive value with SCID diagnoses as the reference standard and conducted receiver operating curve (ROC) analyses; we also assessed internal consistency and test-retest reliability.
RESULTS: Of 253 participants, the SCID classified 10.3% with major depression and 14.6% with generalized anxiety disorder. Among the depression measures, the PHQ-9 had the highest sensitivity (84%). Specificity was generally higher than sensitivity, and was highest for the HADS-D with a cut-point of 11 (95%). In ROC analyses the area under the curve (AUC) did not differ between depression measures. Among the anxiety measures, sensitivity was highest for the HADS-A with a cut-point of 8 (82%). Specificity ranged from 83% to 86% for all measures except the HADS-A with a cut-point of 8 (68%). The AUC did not differ between anxiety measures.
CONCLUSION: Overall, performance of the depression and anxiety screening measures was very similar, with reasonable psychometric properties for the MS population, suggesting that other factors such as accessibility and ease of use could guide the choice of measure in clinical practice.
Copyright © 2017 The Author(s). Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Anxiety; Depression; Multiple sclerosis; Psychometrics; Reliability; Validity

Mesh:

Year:  2017        PMID: 29274564     DOI: 10.1016/j.msard.2017.12.007

Source DB:  PubMed          Journal:  Mult Scler Relat Disord        ISSN: 2211-0348            Impact factor:   4.339


  29 in total

1.  Risk estimation, anxiety, and breast cancer worry in women at risk for breast cancer: A single-arm trial of personalized risk communication.

Authors:  Zhuoer Xie; Neil Wenger; Annette L Stanton; Karen Sepucha; Celia Kaplan; Lisa Madlensky; David Elashoff; Jacqueline Trent; Antonia Petruse; Liliana Johansen; Tracy Layton; Arash Naeim
Journal:  Psychooncology       Date:  2019-09-02       Impact factor: 3.894

Review 2.  Psychiatric disorders in multiple sclerosis.

Authors:  Maddalena Sparaco; Luigi Lavorgna; Simona Bonavita
Journal:  J Neurol       Date:  2019-06-13       Impact factor: 4.849

3.  Screening young adult cancer survivors with the PROMIS Depression Short Form (PROMIS-D-SF): Comparison with a structured clinical diagnostic interview.

Authors:  Christopher J Recklitis; Jaime E Blackmon; Grace Chang
Journal:  Cancer       Date:  2020-01-08       Impact factor: 6.860

4.  Differences in anxiety among patients with liver cirrhosis with different compensation abilities.

Authors:  Mengdang Ou; Xiaozhen Guo; Ying Li; Haili Zhang; Ting Liu; Qun Liu; Wen Wei; Xiaoqing Luo; Yanyan Zhang
Journal:  Am J Transl Res       Date:  2022-07-15       Impact factor: 3.940

5.  Demographic, clinical, and symptomatic correlates of subjective sleep quality in adults with multiple sclerosis.

Authors:  Katie L J Cederberg; Brenda Jeng; Jeffer E Sasaki; E Morghen Sikes; Stephanie L Silveira; Gary Cutter; Robert W Motl
Journal:  Mult Scler Relat Disord       Date:  2021-08-08       Impact factor: 4.808

6.  Sex differences in predictors of illness intrusiveness in persons with multiple sclerosis.

Authors:  Lindsay O Neto; Elizabeth S Gromisch; Jessica Sloan; Tuula Tyry; Frederick W Foley
Journal:  Qual Life Res       Date:  2018-10-17       Impact factor: 4.147

7.  Study protocol for a sequential multiple assignment randomized trial (SMART) to improve physical activity in employed women.

Authors:  Susan W Buchholz; JoEllen Wilbur; Shannon Halloway; Michael Schoeny; Tricia Johnson; Sachin Vispute; Spyros Kitsiou
Journal:  Contemp Clin Trials       Date:  2019-12-30       Impact factor: 2.226

8.  Symptom clusters and quality of life in persons with multiple sclerosis across the lifespan.

Authors:  Stephanie L Silveira; Katie L J Cederberg; Brenda Jeng; E Morghen Sikes; Brian M Sandroff; Catherine D Jones; Robert W Motl
Journal:  Qual Life Res       Date:  2020-11-05       Impact factor: 4.147

9.  Anxiety and depression affect performance on the symbol digit modalities test over time in MS and other immune disorders.

Authors:  Ruth Ann Marrie; Ronak Patel; Charles N Bernstein; James M Bolton; Lesley A Graff; James J Marriott; Carol A Hitchon; Chase R Figley; Jennifer Kornelsen; John D Fisk
Journal:  Mult Scler       Date:  2020-09-25       Impact factor: 6.312

10.  Mechanisms of change in depression and anxiety within a mind-body activity intervention for chronic pain.

Authors:  Victoria A Grunberg; Ryan A Mace; Sarah M Bannon; Jonathan Greenberg; Jafar Bakhshaie; Ana-Maria Vranceanu
Journal:  J Affect Disord       Date:  2021-06-05       Impact factor: 6.533

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.